Navigation Links
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Date:12/3/2008

s the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody being studied for the treatment of RA. Studies demonstrate that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. The extensive clinical development program conducted by Roche includes five Phase III clinical studies and has enrolled more than 4,000 patients in 41 countries, including the United States. Four Phase III studies are completed and have reported meeting their primary endpoints. A fifth Phase III study, the LITHE study evaluating ACTEMRA in RA is an ongoing two-year study, which is expected to report complete data evaluating the effects of ACTEMRA on the inhibition of structural joint damage in 2009. ACTEMRA is currently under review in the United States and Europe.

ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan.

The serious adverse reactions reported in ACTEMRA clinical studies include serious infections, gastrointestinal perforations and hypersensitivity reactions including anaphylaxis. The most common adverse reactions reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, hypertension and increased ALT. Increases in liver enzymes (ALT and AST) were seen in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical outcomes.
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
3. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
4. MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
10. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
11. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 LifeNet Health ... total hiring for 2015 to more than 160 people. ... increased demand for LifeNet Health,s innovative bio-implants, which are ... more patients to be served. It also is a ... industry. "The growth and success of LifeNet ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/ltwldz/surgicaloperating ... "Surgical/Operating Microscopes Market by Application & End User ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to reach $806.6 million by 2020 from $402.2 ... from 2015 to 2020. , ,Major factors fueling ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2
... Dec. 13, 2010 The creators of the innovative Pill Timer, ... and a much needed medication management system to pediatric patients ... Broward General, in Fort Lauderdale, Florida. Representatives ... be onsite Wednesday, December 15, from 1-3 pm distributing the ...
... IRVINE, Calif., Dec. 13, 2010 Masimo ... that a new clinical study demonstrating the accuracy of ... presented last week at the American Association of ... in Las Vegas. The largest gathering of respiratory care ...
Cached Medicine Technology:Med Time Technology, Inc. Teams up with Give A Smile, Inc. to Provide Pill Timer™ Kits and Toys to Children and Parents at the Chris Evert Children's Hospital of Broward General 2New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 2New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 3New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 4New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 5New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 6
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
(Date:5/29/2015)... 29, 2015 The Global Allopurinol ... study on the current state of the Allopurinol ... key statistics on the state of the industry ... direction for companies and individuals interested in the ... the industry including definitions, classifications, applications and industry ...
(Date:5/29/2015)... Mirada, CA (PRWEB) May 29, 2015 ... traumatic brain injuries with the help of their licensed ... mild traumatic brain injuries can lead to an extensive ... impairments; these effects can arise at any time after ... can be caused by any bump or jolt to ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by ... in Montreal from May 14-19th. This global event sets ... around the world; dedicating itself exclusively to cosmetic medicine. ... plastic surgeons to attend this year’s meeting. , Among ... Vitenas was given the honor of sitting at the presenter’s ...
(Date:5/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... in the vulvar region and can cause significant physical, ... understands the major life altering disorder of Vulvodynia. The ... exclusion. At Women’s Excellence in Endometriosis, they realize that ... If a patient is experiencing any of these symptoms, ...
Breaking Medicine News(10 mins):Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:Healthpointe’s Los Angeles County Clinics Are Now Offering Treatment for Mild Traumatic Brain Injuries 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical ... ) focused on bringing the life saving ... pleased to announce that between February 15, 2009, and today, ... or 12 percent. This follows the announcement on Feb. ...
... CORPS, April 6 The United States Marine Corps ... 2009 when the city opens its doors to the ... activities throughout the Chicagoland area. "Established to recognize ... the cities from which they came, Marine Week also ...
... The nation’s most trusted distributor of plasma products, vaccines and critical-care ... well as new Fluzone® return policy. , ... (Vocus) ... vaccine distribution marketplace, FFF Enterprises, Inc., is pleased to ...
... stumbled across a cure for high blood pressure and heart disease during ... ... 2009 -- The Elmore Oil Company, a Bendigo based company who manufactures ... a double blind placebo controlled trial for their flagship product, Elmore Oil., ...
... 5 Parents can have a tremendous impact on ... learning potential. By using techniques that stimulate the brain ... enhance the child,s awareness of its environment and comprehensive ... Kang announces the launch of Spotlight Baby. Kang says, ...
... Helps Ensure Physicians Can Access Critical Patient ... From the floor of the HIMSS09 Annual ... MDRX ) today introduced Allscripts Remote(TM), a ... virtually anytime, anywhere access to and control ...
Cached Medicine News:Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Marine Corps Launches Inaugural Marine Week in Chicago, May 11-17 2Health News:Marine Corps Launches Inaugural Marine Week in Chicago, May 11-17 3Health News:FFF Named the Exclusive Distributor of Fluzone for GPOs & Announces New Fluzone Return Policy 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2Health News:Spotlight Baby Provides Parents with Educational Programs and Eco-Friendly Products to Support Babies in Reaching Their Full Developmental Potentials 2Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 2Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 3Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 4Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 5
The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
... A revolutionary new agar plate for economically screening ... this biplate with the urine specimen. If the ... the chromogenic side of the biplate will 3 ... E. coli, the BluEcoli™ Urine Biplate is a ...
... The Trinity Biotech Captia™ Legionella ... (ELISA) is intended for the ... (IgG and IgM) to Legionella ... serum from patients with clinical ...
SDA is a patented isothermal amplification technology capable of generating billions of copies of target molecules from a single DNA or RNA template in just minutes....
Medicine Products: